The burden of COPD in the USA: results from the Confronting COPD survey
The burden of COPD in the USA: results from the Confronting COPD survey
复制标题
DOI：
10.1016/s0954-6111(03)80028-8
复制
发表时间：
2003-03-01
影响因子：
4.3
通讯作者：
Borker, R
中科院分区：
文献类型：
--
作者：
Halpern, MT;Stanford, RH;Borker, R
慢性阻塞性肺病 (COPD) 是一种进行性气流受限疾病，无法完全逆转，具有慢性咳嗽和呼吸困难等致残症状。尽管美国的许多研究评估了慢性阻塞性肺病对医疗保健系统和社会的影响，但轻至中度慢性阻塞性肺病患者或符合慢性阻塞性肺病症状标准但尚未接受此诊断的患者的医疗资源利用（特别是门诊服务和药物使用）的数据有限或无法获得。为了填补目前对该疾病影响的认识空白，我们对北美和欧洲“面对慢性阻塞性肺病”的美国样本中收集的患者数据进行了经济分析，这是首次针对该疾病负担的大规模国际调查。估计每名慢性阻塞性肺病患者的年度医疗资源利用成本为 4119 美元，每名患者的间接（非医疗护理）成本为 1527 美元。因此，每位患者每年的社会成本估计为 5646 美元。调查中的大部分疾病费用与住院治疗有关（2891 美元）。调查结果表明，通过减少症状和预防急性加重来改善 COPD 结局的干预措施可以大大降低与该疾病相关的费用。 (C) 2003 爱思唯尔科学有限公司。
Chronic obstructive pulmonary disease (COPD) is a progressive disorder of airflow limitation that is not fully reversible, with disabling symptoms including chronic cough and dyspnoea. Although a number of studies in the U.S.A. have assessed the impact of COPD on the healthcare system and society, data on healthcare resource utilization (particularly outpatient services and medication use) in patients with mild to moderate COPD, or patients who meet symptom criteria for COPD but have not received this diagnosis, are limited or unavailable. To fill gaps in current knowledge about the impact of this disease, an economic analysis was conducted on the data collected from patients enrolled in the U.S.A. sample of Confronting COPD in North America and Europe, the first large-scale international survey of the burden of the disease.The annual cost of healthcare resource utilization was estimated at US$4119 per patient with COPD, with indirect (non-medical care) costs amounting to US$1527 per patient. The annual estimated societal cost was therefore US$5646 per patient. The majority of disease costs in the survey were associated with inpatient hospitalizations (US$2891).The results of the survey suggest that interventions that improve COPD outcomes by decreasing symptoms and preventing acute exacerbations could substantially decrease the costs associated with this disease. (C) 2003 Elsevier Science Ltd.